Publications by authors named "Habuchi T"
Article Synopsis
- * A study reviewed four cases of bladder cancer in young SMID patients, noting a significant delay (median of 12.5 months) between the first symptoms and diagnosis, indicating a need for better monitoring.
- * Treatment involved radical cystectomy for three patients and transurethral ablation for one, with a median follow-up of 134 months; most patients survived, highlighting the need for timely evaluation of urinary symptoms in this vulnerable population.
Nivolumab plus ipilimumab (NIVO+IPI) has a long-term response rate of 30% for patients with metastatic renal cell carcinoma (mRCC). However, 20% of patients develop primary resistant disease (PRD) to NIVO+IPI and show poor survival outcomes. In this study, we aimed to evaluate the effect of PRD as a second-line treatment in patients with mRCC.
View Article and Find Full Text PDFArticle Synopsis
- Rituximab (RIT) is commonly used to help kidney transplant recipients (KTRs) who are ABO-incompatible, but the effectiveness of valganciclovir (VGCV) in preventing cytomegalovirus (CMV) infection after RIT is uncertain.
- A study of 213 KTRs showed that those receiving VGCV had a significantly higher rate of CMV disease (23.5%) compared to those not receiving it (5.5%), though both groups experienced similar rates of CMV infection.
- The results suggest that insufficient VGCV dosage does not effectively lower CMV disease incidence post-RIT, but following a standard VGCV protocol may be beneficial
Article Synopsis
- The study evaluated the effectiveness and safety of three androgen receptor pathway inhibitors (ARPI) — abiraterone, enzalutamide, and apalutamide — in treating patients with metastatic hormone-sensitive prostate cancer in a real-world setting.
- Records of 668 high-risk patients treated with these drugs were analyzed, comparing prostate-specific antigen (PSA) responses, overall survival, and the incidence of adverse events.
- Results showed no significant differences in overall survival or cancer-specific survival among the three drugs, although abiraterone demonstrated a higher rate of achieving a 99% PSA decline, and enzalutamide had the lowest treatment discontinuation rates.
Article Synopsis
- Androgen receptor signaling inhibitors (ARSIs) have significantly improved the treatment of metastatic castration-sensitive prostate cancer (mCSPC) by influencing prostate-specific antigen (PSA) dynamics, which are critical for assessing disease control.
- A retrospective study involving 552 mCSPC patients was conducted to analyze the impact of PSA nadir, PSA response rate, and time to PSA nadir on oncological outcomes like cancer-specific survival and overall survival.
- Results indicated that achieving a low PSA nadir (≤ 0.02 ng/mL) and a high PSA response rate (≥ 99%) were strong independent predictors of better clinical outcomes, underscoring the importance of monitoring PSA dynamics in patient treatment.
Article Synopsis
- Researchers created and validated a risk model for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with abiraterone acetate (ABI) to better predict patient outcomes.
- The study involved 233 patients from three academic centers and validated the model on a separate group of 282 patients, analyzing factors that influence progression-free survival (PFS2) and overall survival (OS).
- Key findings showed that the model effectively categorized patients into risk groups, with poor-risk patients having significantly lower median PFS2 and OS compared to favorable and intermediate groups, aiding in treatment planning.
Background: Active surveillance for prostate cancer was initiated in the early 2000s. We assessed the long-term outcomes of active surveillance in Japan.
Methods: This multicenter prospective observational cohort study enrolled men aged 50-80 years with stage cT1cN0M0 prostate cancer in 2002 and 2003.
Article Synopsis
- - This fourth edition of the Japanese Clinical Practice Guidelines for Prostate Cancer 2023 was developed by the Japanese Urological Association and involved experts from various related organizations, ensuring a comprehensive approach to prostate cancer management.
- - The guidelines emphasize the use of systematic reviews to inform recommendations for 14 specific clinical questions, with decisions made based on the collective input of 24 guideline development members.
- - A general statement outlines findings from literature searches on areas not covered by systematic reviews, with a focus on updates and changes since the last guidelines published in 2016.
Article Synopsis
- - Arterio-ureteral fistulas (AUFs) are rare but serious complications that require quick medical attention, often arising from surgeries like radical cystectomy.
- - A specific case involved a patient who developed an AUF after robotic surgery for bladder cancer, leading to severe internal bleeding due to urine leaks and infection.
- - The situation was successfully treated using a vascular procedure that involved placing an arterial stent graft to manage the fistula.
Background: Nivolumab plus ipilimumab (NIVO + IPI) is the first-line treatment for patients with metastatic renal cell carcinoma (mRCC). While approximately 40% of patients treated with NIVO + IPI achieve a durable response, 20% develop primary resistance with severe consequences. Therefore, there is a clinical need for criteria to select patients suitable for NIVO + IPI therapy to optimize its therapeutic efficacy.
View Article and Find Full Text PDFImmune checkpoint blockade therapies are widely used for cancer treatment, including advanced renal cell carcinoma (RCC). This study aimed to investigate the impact of zygosity in HLA genes and individual HLA genotypes on the efficacy of an anti-PD-1 Ab, nivolumab, in treating advanced RCC. Patient enrollment was conducted across 23 institutions in Japan from August 19, 2019, to September 30, 2020, with follow-up concluding on March 31, 2021.
View Article and Find Full Text PDFRobot-assisted partial nephrectomy (RAPN) has been shown to be a safe and effective method for treatment of small renal tumors, including clinical T1b renal cell carcinoma (RCC); however, the impact of RAPN for cT1b renal tumors on renal function is not well understood. In this retrospective study, 50 patients who underwent RAPN for cT1b renal tumors were evaluated for pre- and post-operative renal function and perioperative clinical factors. Renal function was assessed using the estimated glomerular filtration rate (eGFR) at baseline and on postoperative days (POD) 1, 7, 30, and 180.
View Article and Find Full Text PDFObjectives: The current study aimed to examine the incidence of perioperative infections and graft viability in ABO-compatible and ABO-incompatible renal transplant recipients.
Methods: We included 643 living donor renal transplant recipients registered in the Michinoku Renal Transplant Network from 1998 to 2021. Patients were divided into the ABO-compatible and ABO-incompatible kidney transplantation groups.
Article Synopsis
- - Axitinib is an oral medication used to treat renal cell carcinoma (RCC) but can cause severe side effects, leading to dose adjustments or discontinuation in patients, which emphasizes the need for better biomarkers to evaluate its effectiveness and adverse events (AEs).
- - The study investigated 80 metastatic RCC patients, analyzing their genetic variants, specifically single nucleotide polymorphisms (SNPs) in three genes (ACE, NOS3, AT1R) that are related to how axitinib works on blood vessels.
- - Results indicated that patients with the ACE deletion allele experienced more hand-foot syndrome and worsened kidney function, while those with the NOS3 G allele had higher rates of proteinuria and multiple AEs
Background: Cardiovascular diseases are still highly prevalent after kidney transplantation. However, little is known about the impact of the timing of rejection episodes on cardiovascular disease. The study aimed to analyze the influence of the timing of rejection episodes on cardiovascular events in recipients of living donor kidney transplantation.
View Article and Find Full Text PDFObjectives: To investigate the efficacy of pharmacotherapy for metastatic non-clear cell renal cell carcinoma (nccRCC) in Japanese population.
Methods: In this retrospective analysis, we compared the time to treatment failure (TTF) for molecular-targeted agents as first-line therapy, or nivolumab therapy as sequential therapy between ccRCC and nccRCC using the data of Japanese metastatic RCC patients registered in the Michinoku Japan Urological Cancer Study Group database.
Results: In total, 511 cases of ccRCC and 77 cases of nccRCC were treated with pharmacotherapy.
A 66-year-old male was diagnosed with cT4N0M1b small-cell neuroendocrine carcinoma of the prostate. Four months after the administration of combined androgen blockade, multiple novel metastatic regions in the lung and liver and progression of bone metastasis were observed. The patient was referred to our hospital because of biochemical and radiographic progression after four cycles of docetaxel as a first-line therapy for castration-resistant prostate cancer.
View Article and Find Full Text PDFBackground: To investigate the impact of different urinary diversion (UD) techniques on the peri- and postoperative complications of robot-assisted radical cystectomy (RARC) with ileal conduit.
Methods: We retrospectively analyzed 373 patients undergoing RARC with ileal conduit at 11 institutions in Japan between April 2018 and December 2021. Propensity score weighting was performed to adjust for confounding factors such as age, sex, body mass index, performance status, American Society of Anesthesiologists score, previous abdominal surgery, neoadjuvant chemotherapy, and preoperative high T stage (≥ cT3) and high N stage (≥ cN1).
A recent approach to radiotherapy for prostate cancer is the administration of high doses of radiation to the prostate while minimizing the risk of side effects. Thus, image-guided radiotherapy utilizes advanced imaging techniques and is a feasible strategy for increasing the radiation dose. New radioactive particles are another approach to achieving high doses and safe procedures.
View Article and Find Full Text PDFBackground: The Modified International Metastatic Renal Cell Carcinoma Dataset Consortium model (mIMDC) is a preoperative prognostic model for pT3cN0M0 renal cell carcinoma (RCC). This study aimed to validate the mIMDC and to construct a new model in a localized and locally advanced RCC (LLRCC).
Methods: A database was established (the Michinoku Japan Urological Cancer Study Group database) consisting of 79 patients who were clinically diagnosed with LLRCC (cT3b/c/4NanyM0) and underwent radical nephrectomy from December 2007 to May 2018.
Article Synopsis
- A 75-year-old man with prostate cancer and a history of IgG4-related disease rapidly progressed to diffuse large B-cell lymphoma after receiving androgen deprivation therapy.
- The diagnosis was confirmed through symptoms like dyspnea and back pain, and immunohistochemistry showed a positive estrogen receptor β, suggesting estrogen suppression contributed to the lymphoma's progression.
- Following the cessation of hormone therapy and initiation of R-CHOP treatment, the patient's lymphoma significantly improved, highlighting the important role of estrogen in such cases and the need for careful treatment selection in similar patients.
Article Synopsis
- * Out of 17 participants, TMA symptoms appeared within 72 hours post-transplant, with 16 cases involving ABO incompatibility, and the usage of pre-transplant plasmapheresis was found to be low.
- * Although some gene variants related to TMA were identified in Japanese and East Asian patients, most cases did not lead to significant complications, suggesting that further research is needed to fully understand the genetic risks associated with dnTMA post-KTx.